Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral arterial intervention cases in Connecticut: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 8% on average (237 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 21 | 2,647 | 46% |
| 2020 | 16 | 2,102 | 50% |
| 2021 | 13 |
Iliac, femoropopliteal, and tibial angioplasty, stenting, atherectomy. Professional codes (what the surgeon bills): CPT 37220, 37221, 37224, 37225, 37226, 37227, 37228, 37229, 37230, 37231; the hospital bills MS-DRG 252, 253, 254.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 87% of the cases CMS names in Connecticut; 9 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 97 | 12,468−0.1%/yr | −0.1%/yr | 6.5 | 60% | 16,300 in 2030+4.6%/yr |
| New Jersey | 55 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 39 | 2,246−8.9%/yr | −8.9%/yr | 6.42.0× | 100% | 2,440 in 2030+1.4%/yr |
| Dialysis access |
Peripheral arterial intervention in every state, and its device makers · Every procedure market in Connecticut · Every state · Compare with New York
| 2024 |
| 1,650 |
| 59% |
| 2025 est. | ≈ 1,490 | – |
| 2026 est. | ≈ 1,560 | – |
| 1,999 |
| 53% |
| 2022 | 13 | 1,572 | 54% |
| 2023 | 11 | 1,617 | 57% |
| 2024 | 14 | 1,650 | 59% |
| 2025 from claims | – | 1,490 1,368–1,577 | 63% |
| 2026 forecast | – | 1,556 1,369–1,796 | 62% |
| 2027 forecast | – | 1,557 1,331–1,856 | 63% |
| 2028 forecast | – | 1,557 1,300–1,907 | 64% |
| 2029 forecast | – | 1,557 1,272–1,952 | 65% |
| 2030 forecast | – | 1,555 1,246–1,993 | 65% |
In 2025, 17% inpatient hospital, 12% hospital outpatient, 71% office. The share outside the hospital has moved +5 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| 8,709+2.3%/yr |
| +2.3%/yr |
| 8.0 |
| 77% |
| 12,700 in 2030+6.4%/yr |
| Pennsylvania | 34 | 4,796−11%/yr | −11%/yr | 3.3 | 15% | 4,870 in 2030+0.3%/yr |
| Massachusetts | 34 | 3,386−4.6%/yr | −4.6%/yr | 3.5 | 43% | 4,060 in 2030+3.1%/yr |
| New Hampshire | 5 | 534−11%/yr | −11%/yr | 2.3 | 0% | 1,240 in 2030+15%/yr |
| Rhode Island | 4 | 346−12%/yr | −12%/yr | 3.6 | 54% | 380 in 2030+1.5%/yr |
| Maine | 1 | 250−14%/yr | −14%/yr | 1.5 | 0% | 260 in 2030+0.5%/yr |
| 14 |
| 1,941−9.9%/yr |
| −9.9%/yr |
| 6.11.1× |
| 87% |
| 1,830 in 2030−1%/yr |
| Thrombectomy, IVC filters & venous stents | 1 | 474−5.9%/yr | −5.9%/yr | 1.41.1× | 23% | 420 in 2030−1.9%/yr |
| Carotid revascularization | 1 | 337−3.8%/yr | −3.8%/yr | 1.01.0× | 0% | 320 in 2030−1%/yr |
| Aortic endografts (EVAR/TEVAR) | 1 | 160−6.4%/yr | −6.4%/yr | 0.51.1× | 0% | 150 in 2030−0.8%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Veryan Medical leads with 30% of company spending on these surgeons in 2025, +29 pts on 2024.
In 2025, 10 companies reported engagement with Connecticut’s surgeons worth $9,334 in consulting, speaking, meals and travel tied to these products, about $667 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 58 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.